Isoniazid for the tuberculin reactor: Take it or leave it

Joel Tsevat, W. C. Taylor, J. B. Wong, S. G. Pauker

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The management of the adult tuberculin reactor who has no other risk factors for the development of active tuberculosis is controversial. We performed a decision analysis to address the issue of whether adults 20 to 80 yr of age should take isoniazid to prevent the development of active disease. The analysis uses a Markov simulation, a regression model to calculate the risk of developing tuberculosis at any given time after the discovery of a positive skin test, and estimates from the literature for other probabilities. The analysis favors withholding INH for all age groups, but by only 4 to 17 days of life expectancy, depending on the age of the patient. Quality adjusting and discounting change neither the preferred strategy nor the closeness of the outcome. Sensitivity analyses also underscore the narrowness of the margin. Our analysis reaches different conclusions from previously published analyses. More important than the actual strategy preferred is the minute difference in expected utilities between administering and withholding INH. We suggest that the individual patient decide whether or not these differences are meaningful.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalAmerican Review of Respiratory Disease
Volume137
Issue number1
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Tuberculin
Isoniazid
Tuberculosis
Decision Support Techniques
Life Expectancy
Skin Tests
Age Groups

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Isoniazid for the tuberculin reactor : Take it or leave it. / Tsevat, Joel; Taylor, W. C.; Wong, J. B.; Pauker, S. G.

In: American Review of Respiratory Disease, Vol. 137, No. 1, 01.01.1988, p. 215-220.

Research output: Contribution to journalArticle

Tsevat, Joel ; Taylor, W. C. ; Wong, J. B. ; Pauker, S. G. / Isoniazid for the tuberculin reactor : Take it or leave it. In: American Review of Respiratory Disease. 1988 ; Vol. 137, No. 1. pp. 215-220.
@article{79b857b7787346eaab8b2ca5497ccd10,
title = "Isoniazid for the tuberculin reactor: Take it or leave it",
abstract = "The management of the adult tuberculin reactor who has no other risk factors for the development of active tuberculosis is controversial. We performed a decision analysis to address the issue of whether adults 20 to 80 yr of age should take isoniazid to prevent the development of active disease. The analysis uses a Markov simulation, a regression model to calculate the risk of developing tuberculosis at any given time after the discovery of a positive skin test, and estimates from the literature for other probabilities. The analysis favors withholding INH for all age groups, but by only 4 to 17 days of life expectancy, depending on the age of the patient. Quality adjusting and discounting change neither the preferred strategy nor the closeness of the outcome. Sensitivity analyses also underscore the narrowness of the margin. Our analysis reaches different conclusions from previously published analyses. More important than the actual strategy preferred is the minute difference in expected utilities between administering and withholding INH. We suggest that the individual patient decide whether or not these differences are meaningful.",
author = "Joel Tsevat and Taylor, {W. C.} and Wong, {J. B.} and Pauker, {S. G.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1164/ajrccm/137.1.215",
language = "English (US)",
volume = "137",
pages = "215--220",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - Isoniazid for the tuberculin reactor

T2 - Take it or leave it

AU - Tsevat, Joel

AU - Taylor, W. C.

AU - Wong, J. B.

AU - Pauker, S. G.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The management of the adult tuberculin reactor who has no other risk factors for the development of active tuberculosis is controversial. We performed a decision analysis to address the issue of whether adults 20 to 80 yr of age should take isoniazid to prevent the development of active disease. The analysis uses a Markov simulation, a regression model to calculate the risk of developing tuberculosis at any given time after the discovery of a positive skin test, and estimates from the literature for other probabilities. The analysis favors withholding INH for all age groups, but by only 4 to 17 days of life expectancy, depending on the age of the patient. Quality adjusting and discounting change neither the preferred strategy nor the closeness of the outcome. Sensitivity analyses also underscore the narrowness of the margin. Our analysis reaches different conclusions from previously published analyses. More important than the actual strategy preferred is the minute difference in expected utilities between administering and withholding INH. We suggest that the individual patient decide whether or not these differences are meaningful.

AB - The management of the adult tuberculin reactor who has no other risk factors for the development of active tuberculosis is controversial. We performed a decision analysis to address the issue of whether adults 20 to 80 yr of age should take isoniazid to prevent the development of active disease. The analysis uses a Markov simulation, a regression model to calculate the risk of developing tuberculosis at any given time after the discovery of a positive skin test, and estimates from the literature for other probabilities. The analysis favors withholding INH for all age groups, but by only 4 to 17 days of life expectancy, depending on the age of the patient. Quality adjusting and discounting change neither the preferred strategy nor the closeness of the outcome. Sensitivity analyses also underscore the narrowness of the margin. Our analysis reaches different conclusions from previously published analyses. More important than the actual strategy preferred is the minute difference in expected utilities between administering and withholding INH. We suggest that the individual patient decide whether or not these differences are meaningful.

UR - http://www.scopus.com/inward/record.url?scp=0023828757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023828757&partnerID=8YFLogxK

U2 - 10.1164/ajrccm/137.1.215

DO - 10.1164/ajrccm/137.1.215

M3 - Article

C2 - 3276255

AN - SCOPUS:0023828757

VL - 137

SP - 215

EP - 220

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -